Catch up on the top radiology content of the past week.
|Articles|September 30, 1998
FDA clears IS2’s NuCammas
Canadian gamma camera manufacturer IS2 Research reported this month that the Food and Drug Administration has cleared its two digital single-head gamma cameras for commercialization. The cameras, NuCamma C+ and NuCamma Rx, were designed by
Advertisement
Canadian gamma camera manufacturer IS2 Research reported this month that the Food and Drug Administration has cleared its two digital single-head gamma cameras for commercialization. The cameras, NuCamma C+ and NuCamma Rx, were designed by founder Iain Stark, formerly of Park Medical. They were introduced at this years Society of Nuclear Medicine meeting (SCAN 8/5/98).
NuCamma C+ has a circular field of view, while NuCamma Rx is a rectangular system. The electronics of both units are incorporated into their detectors, and the systems will carry list prices between $150,000 and $190,000. The Nepean, Ontario-based company has almost completed the manufacturing of its first batch of 10 cameras.
Advertisement
Related to this article
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.
Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.
For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.
In the second of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss challenges with evaluating value and ROI for AI software, the physician time required to do so, and possible solutions to facilitate improved clarity and consistency with AI reimbursement.
In the latest episode of her “Breast Imaging in Focus” series, Manisha Bahl, MD, MPH, FSBI, offer pertinent takeaways for breast radiologists from recently issued guidelines for addressing proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
In a study involving over 2,800 people who had brain MRI scans, researchers found that people in the most disadvantaged neighborhoods had 37 percent higher white matter hyperintensity volume (WMHV) on average in comparison to people in the least disadvantaged areas.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears Software That Combines MRI Enhancement of PET Imaging with Automated Quantification of Amyloid and Tau PET
2
Foundation Model-Based Chest X-Ray AI Software Gets FDA Nod
3
Prostate MRI Study Links Lower ACD Values on DWI to Higher Long-Term Risk of Distant Metastases
4
Diagnostic Imaging’s Weekly Scan: September 13 — September 19
5